Bioxytran director Henry Esber resigns; Hana Chen-Walden appointed to board

BIOXYTRAN, INC

Dr. Henry Esber resigned as director effective July 15, 2021, for medical reasons.
Hana Chen-Walden, M.D., a Medical Advisory Board member, elected to fill the vacancy.
Dr. Chen-Walden has 35+ years of regulatory experience; she will receive no cash compensation as director.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Henry Esber

Director

BIXT · BIOXYTRAN, INC

Effective: 2021-07-15
Successor: Hana Chen-Walden
Filed: July 16, 2021, 7:59 PM ET

Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.

Appointed

Hana Chen-Walden

Director

BIXT · BIOXYTRAN, INC

Effective: 2021-07-15
Filed: July 16, 2021, 7:59 PM ET

The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Henry Esber resigned as Director at BIOXYTRAN, INC.

Action: resigned
Role: Director

Exact text from the filing

Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of Bioxytran, Inc. (the “Company”) for medical reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hana Chen-Walden was elected as Director at BIOXYTRAN, INC.

Action: elected
Role: Director

Exact text from the filing

The Company elected Hana Chen-Walden, currently a member of the Company’s Medical Advisory Board, to fill the vacancy created by Dr. Esber’s resignation.

View on SEC.gov

BIOXYTRAN, INC filing history →

Source: SEC EDGAR

accession 0001539497-21-001048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.